Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte, Inc. Appoints Julie A. Brooks as Executive Vice President, General Counsel and Secretary; and Andy Thorson as Executive Vice President, Corporate Strategy and Business Development
SOUTH SAN FRANCISCO, Calif. , March 17, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointments of two executives to its management team. Julie A.
View HTML
Toggle Summary Veracyte, Inc. to Announce Fourth Quarter and Full-Year 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014
SOUTH SAN FRANCISCO, Calif. , March 11, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2013 financial results after close of market on Tuesday, March 18, 2014 . Following the release, Veracyte will host a live conference call
View HTML
Toggle Summary Veracyte Updates Presentation Date and Time at the Cowen and Company 34th Annual Health Care Conference
-- Presentation and Webcast Scheduled for Tuesday, March 4, at 8 a.m. ET --
View HTML
Toggle Summary Veracyte to Present at Cowen and Company 34th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , president and chief executive officer, will present at the Cowen and Company 34 th Annual Health Care Conference on Wednesday, March 5, 2014 at 10 a.m.
View HTML
Toggle Summary Veracyte To Present At 2014 Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO , Feb. 5, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , president and chief executive officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 11:30 a.m. ET in New York .
View HTML
Toggle Summary Veracyte Announces Cigna Coverage for the Afirma® Gene Expression Classifier
SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2013 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of the nation's leading providers of health insurance, has issued a positive coverage policy for
View HTML
Toggle Summary Veracyte, Inc. Announces Third Quarter 2013 Financial Results
-- 3Q Revenue Reached $5.6 Million, Increasing 74% Compared to Prior Year ---- Coverage and Reimbursement Continue to Expand for Afirma® Gene Expression Classifier (GEC) ---- Company Successfully Completed Initial Public Offering on November 4 ---- Conference Call Today at 5 p.m. ET --
View HTML
Toggle Summary Veracyte Presents Data Suggesting Ability of Its Afirma® Gene Expression Classifier To Detect Medullary Thyroid Cancer Among Indeterminate Thyroid Nodule Biopsies
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2013 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced that it presented new data suggesting the ability of its Afirma Gene Expression Classifier (GEC) to accurately identify medullary thyroid cancer (MTC) among thyroid nodule fine needle
View HTML
Toggle Summary Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2013 financial results will be released after close of market on Monday, November 25 , 2013.  Following the release, Veracyte will host a live conference call and webcast
View HTML
Toggle Summary Veracyte, Inc. Announces Closing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif. , Nov. 4, 2013 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its initial public offering of 5,000,000 shares of its common stock resulting in net proceeds of approximately $58.0 million after deducting underwriting discounts and
View HTML